Bayer Starts Phase III Study for Finerenone in Heart Failure Patients

Bayer AG said Monday that it is starting a phase III study for Finerenone for the treatment of patients who suffer from heart failure.
The FINEARTS-HF study’s main goal is to show Finerenone’s superiority over a placebo regarding cardiovascular death and hospitalization or emergency treatment for heart failure, the German pharmaceutical company said.
The study involves 5,500 patients with a left ventricular ejection fraction of at least 40%from 34 countries.
Finerenone is also being studied in two long-term trials in patients with chronic kidney disease and type 2 diabetes.

https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-Starts-Phase-III-Study-for-Finerenone-in-Heart-Failure-Patients-30772556/